AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03163550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose
Study NCT03513302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
Study NCT04035564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium < 1mEq/kg/day
Description: Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
Study NCT04035564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium 5mEq/kg/day
Description: Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
Study NCT01357954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular physiotherapy
Description: The child's regular physiotherapy
Study NCT01357954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Training
Description: Targeted training, 5 days a week for 6 months, up to 30 minutes a day
Study NCT03571672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEFINITY
Description: All subjects will receive a single dose of DEFINITY®
Study NCT02144831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
Description: comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
Study NCT03036436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
Study NCT03093636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)+Decision Support System (DSS)
Description: Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study.
Study NCT03093636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitor (CGM) alone
Description: Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
Study NCT03041142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention
Description: Physical Activity, nutrition and Psychological
Study NCT03041142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine
Description: The participants continued to maintain their routine
Study NCT00724412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Dry Eye relief eye drops
Study NCT00724412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Description: Dry Eye relief eye drops
Study NCT03141463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vvax001 therapeutic cancer vaccine
Description: Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
Study NCT03333148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestle IMPACT Immunonutrition
Description: Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
Study NCT03333148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm B- Standard of Care
Description: No intervention standard of care nutrition (n=146).
Study NCT04403243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight > 85kg for seven days.
Study NCT04403243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 MG
Description: Ruxolitinib - 5mg twice a day per os for ten days
Study NCT04403243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]
Description: Secukinumab - 300mg subcutaneously singly
Study NCT04403243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: standard therapy for COVID 19
Study NCT03873961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy
Description: tissue photobiostimulation for pain reduction and healing enhancement.
Study NCT03873961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level Laser therapy
Description: tissue photobiostimulation for pain reduction and healing enhancement.
Study NCT02441348 — intervention group
Intervention type: BEHAVIORAL
Intervention: Conversation Training Therapy
Description: Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
Study NCT03383783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Study NCT03383783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Study NCT03383783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 500 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Study NCT03383783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as NaF (positive control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Study NCT01538940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal vaccine
Description: 15ug
Study NCT01538940 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intradermal vaccine
Description: 15ug
Study NCT01538940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular vaccine
Description: 15ug
Study NCT01538940 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intramuscular vaccine
Description: 15ug
Study NCT00504140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
Study NCT00504140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alpha
Description: 5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
Study NCT03694873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
Study NCT03694873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
Study NCT01871155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri-jelly
Description: an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement
Study NCT03689075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus Oral Product
Description: Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
Study NCT00902148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polylactic Acid Sheet
Description: SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
Study NCT02606266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
Study NCT00290875 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of Xrays for diagnosis
Study NCT02017145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloraprep
Study NCT01727011 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IPAS
Study NCT01646619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: 10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%.
Study NCT01646619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
Study NCT02046070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide tablets
Study NCT02046070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT02046070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study NCT03518268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx
Description: The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
Study NCT03518268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention consists of 2 sachets a day of placebo, for 6 months
Study NCT00371969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Motivational Interview
Description: The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
Study NCT00371969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Motivational Interview or viewing DVD
Description: Brief motivational interview, viewing a DVD on HIV self-care.
Study NCT00219882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standardized turmeric root extract
Description: 1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
Study NCT02156557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colon KCC Heptapeptide
Description: * Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~* The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~* The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~* We will obtain copies of your endoscopy report and any pathology reports.
Study NCT03554772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (Celecoxib Oral Solution) 62.5 mg
Description: Oral Solution
Study NCT03554772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (Celecoxib Oral Solution) 125 mg
Description: Oral Solution
Study NCT03554772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (Celecoxib Oral Solution) 250 mg
Description: Oral Solution
Study NCT03554772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution
Study NCT03729193 — intervention group
Intervention type: BEHAVIORAL
Intervention: Measuring devices and questionnaires
Description: Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
Study NCT01998893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
Study NCT03761394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing Devices
Description: Pulsewatch system testing application on smartphone with smartwatch.
Study NCT03761394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardea Solo by Cardiac Insight
Description: Gold-standard cardiac monitor for comparison of testing devices.
Study NCT03761394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardea Solo by Cardiac Insight
Description: Gold-standard cardiac monitor for comparison of testing devices.
Study NCT03761394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kardia Mobile by AliveCor
Description: Mobile ECG device for comparison of testing devices during the extended use period.
Study NCT03856008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises focused on flexor muscles
Description: Exercises emphasis flexor muscles.
Study NCT03856008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises focused on extensor muscles
Description: Exercises emphasis extensor muscles.
Study NCT03109028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-to-Peer-Groupintervention
Description: Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors.
Study NCT03109028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based-Intervention
Description: Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology.
Study NCT03109028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gendersensitive-Groupintervention
Description: Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors.
Study NCT03109028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment-Groupintervention
Description: Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;
Study NCT03109028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent-Groupintervention
Description: Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)
Study NCT03109028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Ususal
Description: Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
Study NCT03275688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
Study NCT02783378 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gaviscon Syrup
Study NCT02646839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMacs TCR alpha-beta-Biotin system
Description: Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
Study NCT00941369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine (HOE901)/NPH Insulin
Description: Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring.
Study NCT00941369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (HOE901)/NPH Insulin
Description: Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring.
Study NCT04556032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Ergothioneine 10 mg/d
Description: L-Ergothioneine 10 mg/d
Study NCT04556032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Ergothioneine 25 mg/d
Description: L-Ergothioneine 25 mg/d
Study NCT04556032 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg/d L-Ergothioneine
Study NCT00334360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
Study NCT03513302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nitrate
Description: 2 x 70 mL concentrated beet root juice per day for 14 days.
Study NCT00334360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buspirone
Description: Buspirone, 60 mg orally, will be given during controlled hypothermia.
Study NCT00334360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bus and Dex
Description: the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
Study NCT03263494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitor (CGM)
Description: Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.